drugset / Trial / NCT01245101

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101

RandomizedCrossoverOpen-labelTreatment

Summary

This study will examine whether intensification with raltegravir of a suppressive antiretroviral regimen in HIV infected patients with poor immune restoration has a beneficial effect on cryptic viral replication and the immune system. Specifically, the investigators will examine the effect that raltegravir intensification of ART has on episomal cDNA frequencies, immune activation, CD4+ cell counts and apoptosis, and markers of microbial translocation.

Timeline

Start
2010-11
Primary completion
2012-10
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Raltegravir Other / unclassified 400 mg Oral